← Leaderboards
Raymond Taylor
Biocryst Pharmaceuticals, Inc.
$41,332,087
Attributed
$41,332,087
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $14.9M · FY2013–23$20M$15M$10M$5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$41,332,087 · 1
By mechanism
N01$41,332,087 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Advanced Development”
- David Heimbrook · Leidos Biomedical Research, Inc.$625,894,719
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$378,174,673
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$331,630,794
- David H Reitze · University Of Florida$318,606,363
- Albert Lazzarini · California Institute Of Technology$317,303,333
Research focus
Advanced DevelopmentTherapeutic DevelopmentSupport ContractsResearch And DevelopmentProduct DevelopmentPre-ClinicalBiodefenseFilovirusMedicalEbola VirusTherapeutic CandidateMedical CountermeasureCovid-19Frankfurt-Marburg Syndrome VirusCovid-19 TherapeuticsYellow Fever VirusPhase Ib Clinical Trial2019-Ncov
Grant awards (8)
Development of Medical Countermeasures for COVID-19$440,828
N01 · FY2023 · AI · contact PI
Development of Medical Countermeasures for COVID-19$1,383,666
N01 · FY2021 · AI · contact PI
Development of Medical Countermeasures for COVID-19$2,896,627
N01 · FY2020 · AI · contact PI
Development of Medical Countermeasures for Biodefense and Emerging Diseases$3,557,707
N01 · FY2018 · AI · contact PI
Development of Medical Countermeasures for Biodefense and Emerging Diseases$9,601,843
N01 · FY2016 · AI · contact PI
Development of Medical Countermeasures for Biodefense and Emerging Diseases$3,539,289
N01 · FY2015 · AI · contact PI
Development of Medical Countermeasures for Biodefense and Emerging Diseases$14,916,023
N01 · FY2014 · AI · contact PI
Development of Medical Countermeasures for Biodefense and Emerging Diseases$4,996,104
N01 · FY2013 · AI · contact PI